FNTA (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:2339, FNTA, FPTA, HGNC:3782, MIM:134635, NM_001018676, NM_001018677, NM_002027, NP_002018, NR_033698, PGGT1A, PTAR2, farnesyltransferase, CAAX box, alpha

Omim:OMIM:134635

Id:ENSG00000168522

Hgnc:HGNC:3782

Entrez:2339

Ensembl:ENSG00000168522

Description:farnesyltransferase, CAAX box, subunit alpha

Prenyltransferases can attach either a farnesyl group or a geranylgeranyl group in thioether linkage to the cysteine residue of proteins with a C-terminal CAAX box. CAAX geranylgeranyltransferase and CAAX farnesyltransferase are heterodimers that share the same alpha subunit but have different beta subunits. This gene encodes the alpha subunit of these transferases. Alternative splicing results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 11 and 13. [provided by RefSeq, May 2010]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View FNTA's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with FNTA.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using FNTA.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for FNTA.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with FNTA.

Results found

Linked to

	Label	Description
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 10 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE217115 3 V 5 ALECTINIB MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 10 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE217115 3 V 5 ALECTINIB MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.